

NRG Principal Investigators and Research Associates are cordially invited to a workshop to discuss

NRG-LU003: A Biomarker-Driven Protocol for Previously Treated ALK-Positive NSCLC Patients: The NCI-NRG ALK Master Protocol

Date: Friday, July 13, 2018

Start and End Time: 11:30am – 1pm EST

Learning Objectives:

Following this activity, participants will be better able to:

1. Discuss the significance of the study.
2. Apply standards and procedures required to participate in the trial.
3. Discuss the requirements for pathology review.
4. Overview of statistical design and treatment assignment.

Agenda

Welcome and Introductions – *Erica Field, NRG Oncology*

Background to Non-Small Cell Lung Cancer Trials – *Jeff Bradley, MD, NRG Oncology Lung Cancer Committee Chair*

Protocol Overview – *Shakun Malik, MD, NRG-LU003 Co-Chair*

Blood Assay and Tissue Analysis – *Jennifer Webster, Foundation of Medicine*

Statistical Design – *Chen Hu, PhD, Statistician, NRG Oncology*

Question and Answer Session